Specifically, we reasoned that this strategy could reverse the high lactate-to-glucose ratio within tumors and destabilize tumor metabolism and Tregs, leading to enhanced therapeutic activity when combined with CTLA-4 blockade, based on our prior findings in genetically modified tumor models. Here, CTLA4 is linked to neoplasm.